- Home
- LYRA vs BIAF Comparison
LYRA vs BIAF Comparison
Compare LYRA & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BIAF
- Stock Information
- Founded
- LYRA 2005
- BIAF 2014
- Country
- LYRA United States
- BIAF United States
- Employees
- LYRA N/A
- BIAF N/A
- Industry
- LYRA Medical/Dental Instruments
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LYRA Health Care
- BIAF Health Care
- Exchange
- LYRA Nasdaq
- BIAF Nasdaq
- Market Cap
- LYRA 18.0M
- BIAF 21.4M
- IPO Year
- LYRA 2020
- BIAF 2022
- Fundamental
- Price
- LYRA $0.17
- BIAF $1.31
- Analyst Decision
- LYRA Buy
- BIAF Strong Buy
- Analyst Count
- LYRA 5
- BIAF 1
- Target Price
- LYRA $4.50
- BIAF $6.00
- AVG Volume (30 Days)
- LYRA 2.2M
- BIAF 150.9K
- Earning Date
- LYRA 11-12-2024
- BIAF 11-14-2024
- Dividend Yield
- LYRA N/A
- BIAF N/A
- EPS Growth
- LYRA N/A
- BIAF N/A
- EPS
- LYRA N/A
- BIAF N/A
- Revenue
- LYRA $1,471,000.00
- BIAF $9,367,785.00
- Revenue This Year
- LYRA $13.99
- BIAF $302.41
- Revenue Next Year
- LYRA N/A
- BIAF $15.00
- P/E Ratio
- LYRA N/A
- BIAF N/A
- Revenue Growth
- LYRA 3.37
- BIAF 2813.87
- 52 Week Low
- LYRA $0.17
- BIAF $1.21
- 52 Week High
- LYRA $6.79
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- LYRA 30.70
- BIAF 40.08
- Support Level
- LYRA $0.26
- BIAF $1.21
- Resistance Level
- LYRA $0.28
- BIAF $1.37
- Average True Range (ATR)
- LYRA 0.02
- BIAF 0.08
- MACD
- LYRA -0.01
- BIAF 0.01
- Stochastic Oscillator
- LYRA 1.69
- BIAF 45.45
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.